Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
December 06, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
December 04, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
November 28, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe

FRAMINGHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices,...
November 26, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018

FRAMINGHAM, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
October 01, 2018 07:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel

FRAMINGHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices,...
September 25, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018

FRAMINGHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
September 05, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5

FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today...
August 28, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018

FRAMINGHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
August 16, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018

FRAMINGHAM, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of AC5™ Topical Gel (“AC5™”), today announced that new research...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right